L'Oréal Talc Liabilities: Weil and Ducera Hired to Explore Selling US Claims Outside Bankruptcy

L'Oréal's US unit has hired restructuring counsel Weil Gotshal & Manges and investment bank Ducera Partners to explore offloading its US talc liabilities, most likely by placing them in a separate company and selling that company to an outside investor, The Wall Street Journal reported on Monday, October 5, 2026. The move matters because L'Oréal's talc-asbestos docket grew from about 620 to about 760 US proceedings in the first half of 2026, and because a liability sale, unlike a Chapter 11 case, would change who defends those claims without giving claimants a vote.

Nothing has been signed. No buyer, price, structure or timetable has been reported, and L'Oréal, Weil and Ducera did not immediately respond to requests for comment, according to Reuters' summary of the Journal's report. What has been reported is enough to show the shape of the plan, the precedent it borrows from, and the legal reasons a cosmetics company facing asbestos-in-talc claims in 2026 would look first at a sale rather than a bankruptcy court. This article sets out what is known about the L'Oréal talc liabilities review, what a Delticus-style transaction involves, why the Chapter 11 path has narrowed since 2024, whether the much larger hair relaxer docket is in play, and what each side of the bar should be watching.

Is L'Oréal selling its talc liabilities?

Not yet: L'Oréal is exploring a sale, not executing one. According to the reporting, the US unit's advisers are weighing two related routes. The first is to transfer the tort liabilities into a separate corporate entity and then sell that entity to an outside investor, which would separate the disputed claims from the operating cosmetics business. The second, framed in the reporting as an alternative to Chapter 11, is a transaction similar to Honeywell's 2025 divestiture of asbestos liabilities to Delticus, a company whose business is buying and managing long-tail corporate liabilities. In practice the two descriptions converge: the Honeywell deal was itself a transfer of liabilities to a dedicated vehicle followed by a change of ownership.

The reports describe the exposure as US legal liabilities linked to talc "and other chemical ingredients" in some cosmetic products. That wording is broader than talc alone, and it is the single most important open question in the story, discussed below.

Who are L'Oréal's restructuring advisers?

L'Oréal's US unit is working with Weil Gotshal & Manges as restructuring counsel and Ducera Partners as investment banker. The pairing signals optionality rather than a fixed plan. A restructuring firm and a restructuring-focused bank are the advisers a company retains when it wants to understand every route to finality, including a court-supervised one, even if its stated preference is an out-of-court sale. Their engagement does not mean a bankruptcy filing is planned, and the reporting specifically frames the sale model as a way to address the claims outside Chapter 11.

How many talc lawsuits does L'Oréal face?

About 760 US proceedings alleging asbestos particles in talc-containing cosmetic products were pending against L'Oréal's US subsidiaries as of June 30, 2026, according to the company's half-year report as quoted by Reuters. That compares with about 620 proceedings at December 31, 2025, the figure in L'Oréal's 2025 Universal Registration Document. The company says it strongly contests the claims, and its annual report stated that none of the cases involving its subsidiaries had gone to trial.

Measure	Figure	Source
Talc-asbestos proceedings pending, Dec. 31, 2025	About 620	L'Oréal 2025 Universal Registration Document
Talc-asbestos proceedings pending, June 30, 2026	About 760	L'Oréal half-year report, as reported by Reuters
Six-month increase	About 140 proceedings (roughly 23%)	Calculated from the two figures above
Talc cases against L'Oréal subsidiaries tried to verdict	None, per the company's last annual report	L'Oréal 2025 Universal Registration Document
Federal hair relaxer actions, MDL No. 3060 (all defendants)	12,129 on Sept. 1, 2026	JPML pending-docket report

By the standards of Johnson & Johnson's talc exposure, roughly 760 cases is a small inventory. J&J's ovarian-cancer settlement announced on July 27, 2026 was sized at $5.5 billion and covered about 76,000 claims. But raw counts understate cosmetic-talc risk. The L'Oréal claims are asbestos claims, which typically means mesothelioma, a disease with a short latency-to-death window, high per-case values, and juries that have returned very large verdicts against other talc defendants, including a $966 million Los Angeles verdict against J&J in October 2025. A docket that is growing by about 23% every six months, and has never been tested before a jury, is the kind of contingent liability that a buyer will price aggressively and that a seller may prefer to cap.

The company's public position on the product has not changed. In 2020, when L'Oréal, Chanel and Revlon were reported to be moving away from talc in some products, L'Oréal said it had not found a replacement that performed as well and that it required suppliers to certify annually that its talc was asbestos-free, backed by in-house testing.

How would a liability sale like Honeywell's Delticus deal work?

A liability sale moves a defined set of tort claims, and usually the insurance assets that respond to them, into a standalone subsidiary. The parent and the buyer capitalize that subsidiary with cash, and the buyer then acquires its equity. After closing, the subsidiary, now owned by the acquirer, defends, settles and pays the claims; the former parent typically receives an indemnity and records a one-time charge. Claims are not released, extinguished or channeled. They are simply defended by a different owner with a fixed pot of money.

Delticus has done this three times with major US industrial companies, and the public terms give the clearest available benchmark for what a L'Oréal talc liabilities deal could look like.

Transaction	Date	Liabilities transferred	Funding at closing	Notes
ITT to Delticus	Announced July 1, 2021	InTelCo Management LLC, holding asbestos and other long-term liabilities plus related insurance assets	About $398 million contributed by ITT	Delticus then described as an affiliate of Warburg Pincus
Ingersoll Rand to Delticus	Effective June 10, 2024	100% of three subsidiaries holding asbestos liabilities and insurance assets	$188.5 million total: $143.5 million insurance settlement proceeds, $35 million from Delticus affiliates, $10 million from Ingersoll Rand	Delticus described as owned by Third Point affiliates
Honeywell to Delticus	Announced late September 2025	All legacy Bendix asbestos liabilities and certain non-Bendix asbestos liabilities	About $1.68 billion in cash from Honeywell and Delticus, plus insurance assets	Honeywell guided to a one-time after-tax loss of about $115 million and more than $100 million a year in free-cash-flow improvement; Delticus provides full indemnification

Three features of these deals are directly relevant to L'Oréal.

First, they all involved asbestos claims with decades of actuarial history. Buyers could model incidence, settlement values and run-off curves from long claim records. L'Oréal's cosmetic-talc docket is younger and has no verdicts, so a buyer has less data and more uncertainty, which tends to raise the capital a seller must contribute.

Second, the capital came from a mix of corporate cash, buyer equity and insurance. The Ingersoll Rand transaction was funded mostly with insurance settlement proceeds; Honeywell's was dominated by cash. How much insurance coverage L'Oréal's US unit has for talc claims, and whether insurers would consent to an assignment or settle into the vehicle, is unknown and will drive the economics.

Third, the transferred entities were capitalized to pay claims over a long horizon. Whether the vehicle is adequately capitalized is the question claimants' counsel will ask first, because a liability-holding company that runs out of money leaves claimants with judgments against an empty shell.

Will L'Oréal file for bankruptcy over talc claims?

Nothing reported suggests a bankruptcy filing is planned; the advisers are expressly studying ways to resolve the claims outside Chapter 11. The legal landscape explains why. On June 27, 2024, in Harrington v. Purdue Pharma L.P., the Supreme Court held 5-4, in an opinion by Justice Gorsuch, that the Bankruptcy Code does not authorize a Chapter 11 plan to release claims against non-debtor third parties without the claimants' consent. That ruling removed the tool on which most solvent-parent mass tort bankruptcies relied: the ability to put a subsidiary into Chapter 11 and obtain a release for the healthy parent.

Then, on March 31, 2025, Judge Christopher Lopez of the US Bankruptcy Court for the Southern District of Texas refused to confirm the prepackaged plan in Red River Talc, Johnson & Johnson's third attempt to resolve talc claims through a subsidiary bankruptcy, citing defects in the solicitation and voting process and problems with the plan's third-party releases. The Texas Two-Step model that J&J used across its LTL Management and Red River filings has not produced a confirmed talc plan for a solvent parent.

There is an important twist for L'Oréal. Purdue left intact the one statutory exception Congress wrote for mass harm: asbestos. Section 524(g) of the Bankruptcy Code permits a channeling injunction that sends present and future asbestos claims to a trust, including claims against certain non-debtors, if the plan meets the statute's requirements, among them approval by at least 75% of voting claimants. L'Oréal's talc claims allege asbestos contamination, so in principle a Section 524(g) Trust is available for them in a way it is not for opioid, hair relaxer or other non-asbestos tort claims. The Red River outcome shows the practical difficulty: the 75% vote must be real, the solicitation must be clean, and a solvent parent must contribute substantially. A sale avoids the vote, the court and the years of litigation that Section 524(g) cases involve, at the price of paying a buyer up front to take the risk.

Route	Court supervision	Claimant vote	Releases parent?	Covers non-asbestos claims?
Liability sale (Delticus model)	None required	No	Not a legal release; parent relies on separation and buyer indemnity	Possible, if the claims are transferred, but claimants' rights against the parent are not cut off by the sale itself
Chapter 11 with Section 524(g) trust	Bankruptcy court	Yes, at least 75% of voting asbestos claimants	Yes, if statutory requirements are met	No; Section 524(g) is limited to asbestos claims
Chapter 11 without Section 524(g)	Bankruptcy court	Yes	Only with consent after Purdue	Yes, but releases of non-debtors require consent
Global Settlement outside bankruptcy	Mass tort court or none	Individual opt-in, usually subject to a participation threshold	Only for participating claimants	Yes

Does L'Oréal's plan affect hair relaxer lawsuits?

It is not yet known. The reporting describes liabilities tied to talc "and other chemical ingredients" and notes that the company also faces thousands of lawsuits alleging its hair relaxer products cause cancer, but it does not say whether those claims are within the scope of the advisers' work or of any eventual sale. The distinction is large. The federal hair relaxer litigation, In re Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3060 before Judge Mary M. Rowland in the Northern District of Illinois, held 12,129 pending actions in the Judicial Panel on Multidistrict Litigation (JPML) report of September 1, 2026, roughly sixteen times the size of L'Oréal's talc docket, though that count includes cases against other manufacturers such as Revlon and Strength of Nature.

Several features of the hair relaxer docket make it harder to sell than the talc claims:

• No asbestos carve-out. If the hair relaxer claims ever went through Chapter 11, Purdue would bar a nonconsensual release of the parent. A sale is therefore the only route to separation that does not require claimant consent, which makes the question of scope more consequential for hair relaxer than for talc.
• Unresolved causation. The defendants' joint Rule 702 motion to exclude the plaintiffs' General Causation experts has been fully briefed since June 2026 and remains undecided. A buyer pricing hair relaxer risk today is pricing a binary outcome: if the experts are excluded, the federal inventory faces summary judgment; if they are admitted, the first Bellwether Trial is set for September 7, 2027.
• Government plaintiffs. In September 2026 Arizona Attorney General Kristin Mayes filed a state consumer fraud lawsuit against L'Oréal USA over hair relaxers sold under brands including Dark and Lovely, Optimum and Mizani, the first state enforcement action over relaxer cancer warnings. State consumer protection claims seek penalties and injunctive relief tied to ongoing conduct, which is difficult to transfer to a liability buyer.
• Parent already out of the MDL. On May 7, 2025, Judge Rowland dismissed the French parent, L'Oréal S.A., from MDL No. 3060 for lack of personal jurisdiction, finding the evidence did not show it placed the products into the US stream of commerce or controlled its subsidiaries' day-to-day operations. The defendants that remain are the US entities, which is the unit the advisers are reportedly working for.

Until scope is disclosed, hair relaxer counsel should treat the reporting as a signal about the company's appetite for finality rather than as a change to their cases.

What happens to pending talc claims if L'Oréal sells the liabilities?

Pending talc claims would continue; a sale changes who defends and pays them, not whether they exist. Outside bankruptcy there is no automatic stay, no claims bar date and no channeling injunction. Plaintiffs would keep litigating in the state and federal courts where their cases are pending, and the newly owned liability entity, funded with whatever capital the deal provides, would make the defense and settlement decisions.

Four legal pressure points follow from that structure, and they are where any challenge would be fought:

1. Fraudulent transfer. State voidable-transfer statutes allow creditors, including tort claimants, to unwind transfers made with intent to hinder creditors or for less than reasonably equivalent value while leaving the transferor unable to pay. Whether the vehicle is capitalized to pay foreseeable claims is the central fact.
2. Successor and alter-ego liability. Plaintiffs may continue to name the operating company or affiliated entities on theories that the separation was a sham or that the operating business remains liable for its own conduct. How cleanly the liabilities are carved out, and which entity manufactured, distributed and sold the products, will matter.
3. Insurance. Policies that respond to talc claims may not be assignable without insurer consent. If coverage stays with the operating company, claimants may still pursue it; if it moves to the vehicle, its limits become part of the capitalization analysis.
4. Disclosure. Settlements negotiated with a liability acquirer may follow different economics from those negotiated with a consumer-brand parent concerned about reputation, trial publicity and Punitive Damages. Plaintiffs' firms will watch whether settlement posture changes after any closing.

None of this prevents new talc suits. The Statute of Limitations in asbestos cases generally runs from diagnosis or discovery of the disease, so future mesothelioma claimants would sue whichever entity holds the liabilities at that time, and possibly the operating company as well.

Timeline of L'Oréal talc and chemical-ingredient litigation

Date	Event
June 2020	L'Oréal, Chanel and Revlon reported to be moving away from talc in some cosmetic products; L'Oréal says no alternative performs as well
July 1, 2021	ITT announces sale of its asbestos-liability subsidiary to Delticus
Feb. 6, 2023	JPML centralizes hair relaxer cases as MDL No. 3060 before Judge Rowland
June 10, 2024	Ingersoll Rand completes sale of asbestos subsidiaries to Delticus
June 27, 2024	Supreme Court decides Harrington v. Purdue Pharma, barring nonconsensual third-party releases outside the asbestos context
Mar. 31, 2025	Bankruptcy court rejects J&J's Red River Talc plan
May 7, 2025	L'Oréal S.A. dismissed from MDL No. 3060 for lack of personal jurisdiction
Late Sept. 2025	Honeywell announces divestiture of Bendix and other asbestos liabilities to Delticus
Dec. 31, 2025	About 620 talc-asbestos proceedings pending against L'Oréal US subsidiaries
June 30, 2026	About 760 talc-asbestos proceedings pending
July 27, 2026	J&J announces $5.5 billion ovarian talc settlement framework
Sept. 2026	Arizona sues L'Oréal USA over hair relaxer cancer warnings
Oct. 5, 2026	WSJ reports L'Oréal US unit has retained Weil and Ducera to explore a liability sale
Sept. 7, 2027	First hair relaxer bellwether trial scheduled in MDL No. 3060

What it means for claimants' counsel, defendants and funders

mesothelioma and talc claimants' counsel. The near-term effect is leverage. A company preparing to sell a liability portfolio wants a clean, quantifiable inventory, which can mean appetite for inventory settlements before a deal closes, and resistance to precedent-setting verdicts that would raise the price. Counsel with trial-ready cosmetic-talc cases against L'Oréal entities should expect that a first verdict, if one comes before any sale, would be priced into the transaction. Counsel should also identify now which entity sold each product and which insurers responded, because those facts decide who remains answerable after a carve-out.

Hair relaxer counsel. The scope question is decisive. If hair relaxer claims are included, the economics of MDL No. 3060 settlement talks could shift from a consumer-brand defendant to a liability acquirer. If they are excluded, the talc review is a separate track. Either way, the Rule 702 ruling remains the event that sets value.

Other cosmetics and personal-care defendants. Honeywell, ITT and Ingersoll Rand were industrial companies with old asbestos tails. A consumer-beauty company using the same model would show that the liability-sale market is open to younger, product-based talc dockets. Companies facing cosmetic-talc claims, and those with talc exposure from historical suppliers, will watch whether a buyer can be found and at what multiple of reserves.

Defense-side and restructuring practitioners. After Purdue and Red River, the menu for a solvent company with a growing mass tort is short: litigate, settle globally with a participation threshold, use Section 524(g) if the claims are asbestos claims, or sell. L'Oréal's review is the clearest test yet of whether the sale route works outside heavy industry.

Litigation funders and lien holders. Funders with positions in talc portfolios against L'Oréal entities should model a change in counterparty. Third-Party Litigation Funding returns depend on time to resolution and on the defendant's settlement posture, both of which a sale could change.

FAQ

Is L'Oréal selling its talc liabilities?

L'Oréal's US unit is exploring a sale of its US talc and chemical-ingredient tort liabilities, according to The Wall Street Journal's October 5, 2026 report, but no transaction, buyer or price has been announced.

How many talc lawsuits does L'Oréal face?

About 760 US proceedings alleging asbestos in talc-containing cosmetics were pending against L'Oréal's US subsidiaries as of June 30, 2026, up from about 620 at the end of 2025.

Will L'Oréal file for bankruptcy over talc claims?

There is no reported plan to file; the advisers are studying alternatives to Chapter 11, including a Honeywell-style sale to a liability acquirer such as Delticus.

Does L'Oréal's plan affect hair relaxer lawsuits?

The reports refer to talc "and other chemical ingredients" but do not say whether hair relaxer claims, which are centralized in MDL No. 3060 in Chicago, are within the scope of any sale.

Can people still sue L'Oréal over talc?

Yes. A liability sale outside bankruptcy does not release or bar claims; it changes which entity defends them, and existing and future claimants can still file suit.

What is Delticus?

Delticus is a US corporate liability acquisition platform that buys subsidiaries holding long-tail liabilities, and it has acquired asbestos liabilities from ITT, Ingersoll Rand and Honeywell, the last in a deal funded with about $1.68 billion in cash plus insurance assets.